Paragon 28, Inc. (FNA)

$9.8

+0.15

(+1.55%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Paragon 28, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 51.00M → 60.56M (in $), with an average increase of 8.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.33M → -19.55M (in $), with an average decrease of 134.8% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 28.0% return, outperforming this stock by 74.3%

Performance

  • $9.57
    $9.91
    $9.80
    downward going graph

    2.35%

    Downside

    Day's Volatility :3.43%

    Upside

    1.11%

    downward going graph
  • $7.95
    $19.72
    $9.80
    downward going graph

    18.88%

    Downside

    52 Weeks Volatility :59.69%

    Upside

    50.3%

    downward going graph

Returns

PeriodParagon 28, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-17.44%
-0.4%
0.0%
6 Months
3.27%
8.5%
0.0%
1 Year
-46.27%
4.2%
-1.2%
3 Years
-47.62%
13.9%
-19.2%

Highlights

Market Capitalization
800.0M
Book Value
$2.15
Earnings Per Share (EPS)
-0.58
Wall Street Target Price
18.0
Profit Margin
-22.11%
Operating Margin TTM
-18.54%
Return On Assets TTM
-7.84%
Return On Equity TTM
-30.03%
Revenue TTM
216.4M
Revenue Per Share TTM
2.64
Quarterly Revenue Growth YOY
17.599999999999998%
Gross Profit TTM
148.9M
EBITDA
-21.8M
Diluted Eps TTM
-0.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.44
EPS Estimate Next Year
-0.31
EPS Estimate Current Quarter
-0.09
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Paragon 28, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 83.67%

Current $9.80
Target $18.00

Company Financials

FY19Y/Y Change
Revenue
106.3M
-
Net Income
3.1M
-
Net Profit Margin
2.93%
-
FY20Y/Y Change
Revenue
111.0M
↑ 4.42%
Net Income
3.5M
↑ 12.22%
Net Profit Margin
3.15%
↑ 0.22%
FY21Y/Y Change
Revenue
147.5M
↑ 32.87%
Net Income
-13.7M
↓ 491.45%
Net Profit Margin
-9.29%
↓ 12.44%
FY22Y/Y Change
Revenue
181.4M
↑ 23.0%
Net Income
-67.3M
↑ 391.68%
Net Profit Margin
-37.12%
↓ 27.83%
FY23Y/Y Change
Revenue
216.4M
↑ 19.3%
Net Income
-47.8M
↓ 28.94%
Net Profit Margin
-22.11%
↑ 15.01%
Q3 FY22Q/Q Change
Revenue
46.0M
↑ 8.25%
Net Income
-9.7M
↑ 1.26%
Net Profit Margin
-21.14%
↑ 1.46%
Q4 FY22Q/Q Change
Revenue
51.5M
↑ 11.96%
Net Income
-38.8M
↑ 298.63%
Net Profit Margin
-75.26%
↓ 54.12%
Q1 FY23Q/Q Change
Revenue
52.0M
↑ 1.03%
Net Income
-9.1M
↓ 76.65%
Net Profit Margin
-17.4%
↑ 57.86%
Q2 FY23Q/Q Change
Revenue
51.0M
↓ 1.97%
Net Income
-10.9M
↑ 20.39%
Net Profit Margin
-21.36%
↓ 3.96%
Q3 FY23Q/Q Change
Revenue
52.8M
↑ 3.48%
Net Income
-8.3M
↓ 23.55%
Net Profit Margin
-15.79%
↑ 5.57%
Q4 FY23Q/Q Change
Revenue
60.6M
↑ 14.74%
Net Income
-19.6M
↑ 134.75%
Net Profit Margin
-32.3%
↓ 16.51%
FY19Y/Y Change
Total Assets
74.6M
-
Total Liabilities
47.3M
-
FY20Y/Y Change
Total Assets
97.6M
↑ 30.89%
Total Liabilities
26.1M
↓ 44.83%
FY21Y/Y Change
Total Assets
234.5M
↑ 140.35%
Total Liabilities
42.4M
↑ 62.28%
FY22Y/Y Change
Total Assets
254.1M
↑ 8.34%
Total Liabilities
113.2M
↑ 167.25%
FY23Y/Y Change
Total Assets
340.7M
↑ 34.08%
Total Liabilities
163.0M
↑ 43.98%
Q3 FY22Q/Q Change
Total Assets
257.0M
↓ 3.05%
Total Liabilities
85.6M
↓ 2.85%
Q4 FY22Q/Q Change
Total Assets
254.1M
↓ 1.11%
Total Liabilities
113.2M
↑ 32.23%
Q1 FY23Q/Q Change
Total Assets
313.5M
↑ 23.39%
Total Liabilities
108.4M
↓ 4.23%
Q2 FY23Q/Q Change
Total Assets
300.8M
↓ 4.05%
Total Liabilities
101.8M
↓ 6.08%
Q3 FY23Q/Q Change
Total Assets
293.4M
↓ 2.49%
Total Liabilities
99.6M
↓ 2.15%
Q4 FY23Q/Q Change
Total Assets
340.7M
↑ 16.14%
Total Liabilities
163.0M
↑ 63.59%
FY19Y/Y Change
Operating Cash Flow
12.3M
-
Investing Cash Flow
-17.5M
-
Financing Cash Flow
6.5M
-
FY20Y/Y Change
Operating Cash Flow
1.1M
↓ 90.97%
Investing Cash Flow
-10.3M
↓ 40.88%
Financing Cash Flow
24.0M
↑ 266.88%
FY21Y/Y Change
Operating Cash Flow
-3.3M
↓ 398.56%
Investing Cash Flow
-35.5M
↑ 243.96%
Financing Cash Flow
131.1M
↑ 445.96%
FY22Y/Y Change
Operating Cash Flow
-49.2M
↑ 1382.7%
Investing Cash Flow
-60.7M
↑ 71.01%
Financing Cash Flow
39.5M
↓ 69.88%
Q3 FY22Q/Q Change
Operating Cash Flow
-12.1M
↓ 15.52%
Investing Cash Flow
-5.5M
↓ 12.45%
Financing Cash Flow
1.2M
↑ 729.93%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.2M
↑ 9.25%
Investing Cash Flow
-7.2M
↑ 29.33%
Financing Cash Flow
2.6M
↑ 109.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-14.1M
↑ 6.27%
Investing Cash Flow
-7.6M
↑ 5.27%
Financing Cash Flow
69.4M
↑ 2620.27%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.3M
↑ 37.57%
Investing Cash Flow
-15.3M
↑ 102.11%
Financing Cash Flow
-2.5M
↓ 103.66%
Q3 FY23Q/Q Change
Operating Cash Flow
-14.1M
↓ 27.03%
Investing Cash Flow
-22.0M
↑ 44.34%
Financing Cash Flow
-1.4M
↓ 46.73%

Technicals Summary

Sell

Neutral

Buy

Paragon 28, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Paragon 28, Inc.
Paragon 28, Inc.
-0.2%
3.27%
-46.27%
-47.62%
-47.62%
Stryker Corporation
Stryker Corporation
-7.86%
22.48%
7.72%
25.93%
78.65%
Boston Scientific Corp.
Boston Scientific Corp.
-0.16%
34.53%
27.96%
63.7%
92.76%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-7.63%
23.69%
0.24%
-4.12%
44.62%
Abbott Laboratories
Abbott Laboratories
-3.78%
10.85%
-2.78%
-10.6%
43.98%
Medtronic Plc
Medtronic Plc
-5.43%
9.33%
-4.8%
-38.04%
-5.55%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Paragon 28, Inc.
Paragon 28, Inc.
NA
NA
NA
-0.44
-0.3
-0.08
NA
2.15
Stryker Corporation
Stryker Corporation
39.69
39.69
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.01
63.01
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.37
37.37
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
32.79
32.79
5.99
4.33
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.14
25.14
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Paragon 28, Inc.
Paragon 28, Inc.
Buy
$800.0M
-47.62%
NA
-22.11%
Stryker Corporation
Stryker Corporation
Buy
$124.6B
78.65%
39.69
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$99.1B
92.76%
63.01
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$51.7B
44.62%
37.37
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$182.7B
43.98%
32.79
13.96%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-5.55%
25.14
13.0%

Institutional Holdings

  • MVM Partners LLC

    13.14%
  • First Light Asset Management, LLC

    4.61%
  • BlackRock Inc

    4.33%
  • BRAIDWELL LP

    4.06%
  • Vanguard Group Inc

    2.48%
  • Bleichroeder LP

    2.13%

Corporate Announcements

  • Paragon 28, Inc. Earnings

    Paragon 28, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

paragon 28 was established in 2010 as an orthopedic foot and ankle company. the name “paragon 28” was chosen to show that we are exclusively a foot and ankle company, with the “28” representing the number of bones in the foot. we will remain true to that vision. paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. our mission is to strategically build a company around the core principles that drive innovation and quality. relentlessly working to advance the science behind foot and ankle surgery, paragon 28 is passionate about and committed to: - creation and innovation: blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - a focus on service: a customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - efficient practices: meeting the needs of increasing pricing pressures and reimbursemen

Organization
Paragon 28, Inc.
Employees
574
CEO
Mr. Albert DaCosta
Industry
Healthcare

FAQs